Zaprinast
Zaprinast is a phosphodiesterase inhibitor that was first developed in the 1970s by the pharmaceutical company Pfizer. It is most commonly known for its ability to increase the levels of cyclic guanosine monophosphate (cGMP) in the body, which can have various effects on the cardiovascular and nervous systems.
History[edit | edit source]
Zaprinast was first synthesized in the 1970s by Pfizer as a potential treatment for erectile dysfunction. It was one of the first drugs developed to inhibit the enzyme phosphodiesterase (PDE), specifically PDE5, which breaks down cGMP in the body. However, it was never marketed for this use.
Mechanism of Action[edit | edit source]
Zaprinast works by inhibiting the enzyme PDE5, which is responsible for breaking down cGMP in the body. By inhibiting this enzyme, Zaprinast allows cGMP levels to remain high, which can have various effects on the body. For example, high levels of cGMP can cause the smooth muscle in the walls of blood vessels to relax, leading to vasodilation and increased blood flow. This is why Zaprinast was initially investigated as a treatment for erectile dysfunction.
Research and Clinical Uses[edit | edit source]
While Zaprinast was never marketed as a treatment for erectile dysfunction, it has been used in research to study the effects of PDE5 inhibitors and cGMP on the body. For example, it has been used in studies investigating the role of cGMP in the regulation of platelet function and the potential use of PDE5 inhibitors in the treatment of pulmonary hypertension.
In addition to its use in research, Zaprinast has also been investigated as a potential treatment for various other conditions. For example, it has been studied for its potential use in the treatment of glaucoma, due to its ability to increase the outflow of aqueous humor from the eye.
Side Effects and Safety[edit | edit source]
As with any drug, Zaprinast can have side effects. These can include headache, flushing, and dyspepsia, which are common side effects of PDE5 inhibitors. However, because Zaprinast is not currently marketed as a drug, its safety profile is not as well established as that of other PDE5 inhibitors.
See Also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
